Get the Stockscreener App
9.46
4.76%
0.43
After Hours:
9.42
-0.04
-0.42%
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 8.1%Still a Buy? - MarketBeat
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Anavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from HC Wainwright - MarketBeat
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA - The Manila Times
Anavex Submits Breakthrough Oral Alzheimer's Drug to European Regulators | AVXL Stock News - StockTitan
Anavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal - The Manila Times
Anavex Life Sciences (NASDAQ:AVXL) Shares Down 4.1%Time to Sell? - MarketBeat
Nwam LLC Purchases New Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by GSA Capital Partners LLP - MarketBeat
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Reaches New 52-Week HighShould You Buy? - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Shares Up 8.1%Here's Why - MarketBeat
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario - Seeking Alpha
Anavex: Understanding Their Latest Alzheimer's Data News With Caution (NASDAQ:AVXL) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected To Breakeven In The Medium-Term - Simply Wall St
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - The Manila Times
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Anavex Life Sciences (NASDAQ:AVXL) Rating Reiterated by HC Wainwright - MarketBeat
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - StockTitan
Short Interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) Declines By 10.3% - MarketBeat
Examining Anavex Life Sciences Corporation (AVXL) stock is warranted - US Post News
Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Market Insights: Anavex Life Sciences Corporation (AVXL)’s Notable Drop of -2.42, Closing at 5.24 - The Dwinnex
Understanding the Risks of Investing in Anavex Life Sciences Corporation (AVXL) - Knox Daily
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade) (NASDAQ:AVXL) - Seeking Alpha
The time has not yet come to remove your chips from the table: Anavex Life Sciences Corporation (AVXL) - SETE News
Renaissance Technologies LLC Has $1.97 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
A stock that deserves closer examination: Anavex Life Sciences Corporation (AVXL) - US Post News
Anavex Life Sciences Corporation (AVXL) may enjoy gains as insiders got busy in the recent days - Knox Daily
Anavex Life Sciences Corporation [AVXL] Director makes an insider acquire of 2,835 shares worth 10,319. - Knox Daily
Australian Vanadium gets interest for $31 million finance support - Mining.com.au
AVXL Shares Experience Surge in Value - Knox Daily
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near? - Yahoo Finance
Australian Vanadium receives Letter of Interest for US$31 million in debt financing from EXIM - Proactive Investors UK
Ratios Revealed: Decoding Anavex Life Sciences Corporation (AVXL)’s Financial Health - The Dwinnex
Oops! Disney May Have Just Spoiled their Next Marvel Series - Bleeding Fool
A better buy-in window may exist right now for Anavex Life Sciences Corporation (AVXL) - SETE News
Alzheimer's Drugs Market Report Details Size, Share, Demand, Forecast, Trends To 2033 - WhaTech
AVXL’s Market Balancing Act: Weighing Gains and Losses in 2023 - The InvestChronicle
Investing in Anavex Life Sciences Corporation (AVXL) might be a great opportunity, but the stock is a bit overvalued - US Post News
Anavex Life Sciences Corporation (AVXL) receives a Neutral rating from Cantor Fitzgerald - Knox Daily
Market Recap: Anavex Life Sciences Corporation (AVXL)’s Positive Momentum, Closing at 5.21 - The Dwinnex
AVXL Stock Sees Decline of Approximately -8.72% in Last Five Days - Knox Daily
Investors in cash trouble should check out Anavex Life Sciences Corporation (AVXL) - SETE News
Ratios Reveal: Breaking Down Anavex Life Sciences Corporation (AVXL)’s Financial Health - The Dwinnex
Investing in Anavex Life Sciences Corporation (AVXL): What You Must Know - Knox Daily
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire Inc.
A History of Outperforming Analyst Forecasts and Beating the Odds: Anavex Life Sciences Corporation (AVXL) - SETE News
Recent Insider Activity Could Benefit Anavex Life Sciences Corporation (AVXL) - Knox Daily
Market Watch Highlights: Anavex Life Sciences Corporation (AVXL) Ends on an Upturn Note at 6.02 - The Dwinnex
Should investors be concerned about Anavex Life Sciences Corporation (AVXL)? - US Post News
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 - StockTitan
Anavex Life Sciences Corporation (AVXL) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Anavex Life Sciences Corporation [NASDAQ: AVXL] Sees Increase in Stock Value - Knox Daily
Was anything positive for Anavex Life Sciences Corporation (AVXL) stock last session? - US Post News
Market Recap Check: Anavex Life Sciences Corporation (AVXL)’s Positive Finish at 6.36, Up/Down 0.63 - The Dwinnex
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):